Activity of 8F4, a T cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo

The PR1 peptide, derived from the leukemia-associated antigens proteinase 3 and neutrophil elastase, is overexpressed on HLA-A2 in acute myeloid leukemia (AML). We developed a high-affinity T-cell receptor-like murine monoclonal antibody, 8F4, that binds to the PR1/HLA-A2 complex, mediates lysis of AML and inhibits leukemia colony formation. Here, we explored whether 8F4 was active in vivo against chemotherapy-resistant AML, including secondary AML. In a screening model, coincubation of AML with 8F4 ex vivo prevented engraftment of all tested AML subtypes in immunodeficient NSG (NOD scid IL-2 receptor γ-chain knockout) mice. In a treatment model of established human AML, administration of 8F4 significantly reduced or eliminated AML xenografts and extended survival compared with isotype antibody-treated mice. Moreover, in secondary transfer experiments, mice inoculated with bone marrow from 8F4-treated mice showed no evidence of AML engraftment, supporting the possible activity of 8F4 against the subset of AML with self-renewing potential. Our data provide evidence that 8F4 antibody is highly active in AML, including chemotherapy-resistant disease, supporting its potential use as a therapeutic agent in patients with AML.

[1]  Jan Engberg,et al.  Visualization of Myelin Basic Protein (Mbp) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (Hla)-Dr2–Mbp 85–99 Complex , 2000, The Journal of experimental medicine.

[2]  S. Ogawa,et al.  Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation. , 2010, Blood.

[3]  D. Scheinberg,et al.  Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody , 2013, Science Translational Medicine.

[4]  Avital Lev,et al.  Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[5]  E. Freireich,et al.  Natural history of central nervous system acute leukemia in adults , 1981, Cancer.

[6]  N. Ueno,et al.  Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. , 1999, Hematology/oncology clinics of North America.

[7]  W. Hildebrand,et al.  TCR-like Biomolecules Target Peptide/MHC Class I Complexes on the Surface of Infected and Cancerous Cells , 2011, International reviews of immunology.

[8]  Zhiqiang An,et al.  [Therapeutic monoclonal antibodies]. , 2009, Revue medicale de Liege.

[9]  Mark M. Davis,et al.  Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia , 2000, Nature Medicine.

[10]  D. Greiner,et al.  Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. , 1995, Journal of immunology.

[11]  A. Rawat,et al.  Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes. , 2013, Journal of the National Cancer Institute.

[12]  Clive S. Woodhouse,et al.  Macrophage colony-stimulating factor enhances monocyte and macrophage antibody-dependent cell-mediated cytotoxicity. , 1989, Cellular immunology.

[13]  เอกรัฐ รัฐฤทธิ์ธำรง.  Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation , 2009 .

[14]  M. Munsell,et al.  Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. , 2010, Cytotherapy.

[15]  I. Pastan,et al.  Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  K. Parker,et al.  Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. , 1996, Blood.

[17]  A. Barrett,et al.  Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. , 1997, Blood.

[18]  H. Andersson,et al.  Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice. , 2011, Blood.

[19]  Ash A. Alizadeh,et al.  CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.

[20]  Yun Wu,et al.  Broad Cross-Presentation of the Hematopoietically Derived PR1 Antigen on Solid Tumors Leads to Susceptibility to PR1-Targeted Immunotherapy , 2012, The Journal of Immunology.

[21]  J. Dick,et al.  Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. , 2009, Cell stem cell.

[22]  D. McNeel,et al.  Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence , 2012, Expert review of vaccines.

[23]  P. Thall,et al.  PR1 Peptide Vaccine-Induced Immune Response Is Associated with Better Event-Free Survival in Patients with Myeloid Leukemia. , 2007 .

[24]  P. Thall,et al.  PR1 Vaccine Elicited Immunological Response after Hematopoietic Stem Cell Transplantation Is Associated with Better Clinical Response and Event-Free Survival. , 2007 .

[25]  S. Rusakiewicz,et al.  Immunotherapeutic peptide vaccination with leukemia-associated antigens. , 2006, Current opinion in immunology.

[26]  E. Klechevsky,et al.  Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts. , 2008, Cancer research.

[27]  A. Rawat,et al.  TCR Mimic Monoclonal Antibodies Induce Apoptosis of Tumor Cells via Immune Effector-Independent Mechanisms , 2011, The Journal of Immunology.

[28]  G. Weiner,et al.  Rituximab: mechanism of action. , 2010, Seminars in hematology.

[29]  K. Scearce-Levie,et al.  A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo , 2011, Science Translational Medicine.

[30]  R. Gale,et al.  Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Majeti.  Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells , 2011, Oncogene.

[32]  A. Sergeeva,et al.  An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. , 2011, Blood.

[33]  Brian J. Smith,et al.  Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. , 2005, Blood.

[34]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[35]  D. Scheinberg,et al.  Approaching untargetable tumor-associated antigens with antibodies , 2013, Oncoimmunology.

[36]  G. Pruneri,et al.  Human acute leukemia cells injected in NOD/LtSz‐scid/IL‐2Rγ null mice generate a faster and more efficient disease compared to other NOD/scid‐related strains , 2008, International journal of cancer.

[37]  Mark M Davis,et al.  How T cells 'see' antigen , 2005, Nature Immunology.

[38]  Z Reich,et al.  Ligand recognition by alpha beta T cell receptors. , 1998, Annual review of immunology.

[39]  K. Scearce-Levie,et al.  A Therapeutic Antibody Targeting Bace1 Inhibits Amyloid-beta Production in Vivo , 2013 .

[40]  D. Scheinberg,et al.  LYMPHOID NEOPLASIA A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL 1 leukemias , 2014 .

[41]  Wolfram Saenger,et al.  Conformational changes within the HLA‐A1:MAGE‐A1 complex induced by binding of a recombinant antibody fragment with TCR‐like specificity , 2008, Protein science : a publication of the Protein Society.

[42]  M. De la Fuente,et al.  Macrophage and lymphocyte antibody-dependent cellular cytotoxicity in spontaneous leukemogenesis of AKR/J mice. , 1989, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[43]  M. Pistillo,et al.  Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines , 2015, Journal of Translational Medicine.

[44]  M. Czuczman,et al.  Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[46]  A Bagg,et al.  A robust xenotransplantation model for acute myeloid leukemia , 2008, Leukemia.